Mutational Analysis of Circulating Dna and Cells in Patients with Metastatic Colorectal Cancer
نویسندگان
چکیده
منابع مشابه
1619pmutational Analysis of Circulating Dna and Cells in Patients with Metastatic Colorectal Cancer.
J.L. García1, I. Matos1, R. Lozano Mejorada1, E. Fonseca1, R. Benito2, A. Santos-Briz3, A. Brownrigg-Gleeson4, J.M. Hernandez-Rivas5, J.J. Cruz Hernandez1 Oncología Médica, Hospital Clínico de Salamanca, Salamanca, SPAIN Hematología, CIC-IBSAL, Salamanca, SPAIN Pathology, Hospital Clínico de Salamanca, Salamanca, SPAIN Cirugía, Hospital Clínico de Salamanca, Salamanca, SPAIN Hematología, Hospit...
متن کاملKRAS mutational status analysis of peripheral blood isolated circulating tumor cells in metastatic colorectal patients
The present study describes an optimized method for isolating peripheral blood circulating tumor cells (CTCs) and performing KRAS mutation analysis. The approach combines isolation of peripheral blood mononuclear cells and immunomagnetic labeling with CD45 and CD326 human microbeads with KRAS analysis performed with a Therascreen KRAS kit by quantitative PCR. KRAS mutations were detected in the...
متن کاملMutational Analysis of Circulating Tumor Cells from Colorectal Cancer Patients and Correlation with Primary Tumor Tissue
Circulating tumor cells (CTCs) provide a non-invasive accessible source of tumor material from patients with cancer. The cellular heterogeneity within CTC populations is of great clinical importance regarding the increasing number of adjuvant treatment options for patients with metastatic carcinomas, in order to eliminate residual disease. Moreover, the molecular profiling of these rare cells m...
متن کاملMutational analysis and clinical correlation of metastatic colorectal cancer.
BACKGROUND Early identification of mutations may guide patients with metastatic colorectal cancer toward targeted therapies that may be life prolonging. The authors assessed tumor genotype correlations with clinical characteristics to determine whether mutational profiling can account for clinical similarities, differences, and outcomes. METHODS Under Institutional Review Board approval, 222 ...
متن کاملCirculating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer.
BACKGROUND Early indicators of treatment response in metastatic colorectal cancer (mCRC) could conceivably be used to optimize treatment. We explored early changes in circulating tumor DNA (ctDNA) levels as a marker of therapeutic efficacy. PATIENTS AND METHODS This prospective study involved 53 mCRC patients receiving standard first-line chemotherapy. Both ctDNA and CEA were assessed in plas...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Annals of Oncology
سال: 2014
ISSN: 0923-7534
DOI: 10.1093/annonc/mdu358.50